BridgeBio Oncology Therapeutics(BBOT.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
BridgeBio Oncology Therapeutics
BBOT.US
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company’s product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California.
1.880 T
BBOT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock market midday update: BridgeBio's stock price soared 10.67%, trading volume surged, and sector trends have attracted market attention?

    BridgeBio Oncology Therapeutics rose 10.67%; AbbVie fell 3.65%, with a trading volume of $1.488 billion; Revolution Medicines rose 3.83%, with a trading volume of $819 million; Regeneron Pharmaceuticals fell 0.98%, with a trading volume of $657 million; Amgen fell 3.20%, with a market capitalization of $178.1 billion

    Tracking Unusual Activity·
    US
    BBOT
    -0.74%
    Tracking Unusual Activity·
    US
    BBOT
    -0.74%

    BridgeBio Oncology Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BBOT
    -0.74%
    LB filings·
    US
    BBOT
    -0.74%

    BridgeBio Oncology Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    BBOT
    -0.74%
    LB filings·
    US
    BBOT
    -0.74%

    Helix Acquisition Corp. II Releases Proforma Financials Highlighting BridgeBio Oncology Therapeutics Merger

    Helix Acquisition Corp. II has released proforma financial statements following its merger with BridgeBio Oncology Therapeutics, finalized on August 11, 2025. The combined entity is now listed on Nasdaq under the ticker "BBOT." Helix raised $260.9 million through private placement financing, resulting in total funds of $366.8 million for the new company, which aims to develop transformative medicines for genetic diseases and cancers. This announcement serves as a significant update on the merger's financial implications.

    Reuters·
    US
    BBOT
    -0.74%
    Reuters·
    US
    BBOT
    -0.74%

    BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

    Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ( "PIPE" ) , led by Cormorant

    Benzinga·
    US
    HLXB
    0.00%
    US
    BBOT
    -0.74%
    Benzinga·
    US
    HLXB
    0.00%
    US
    BBOT
    -0.74%
    © 2026 Longbridge｜Disclaimer